Comparison of liquid chromatography-tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogens

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 1, 2010, Pages 292-300

  Faupel Badger, Jessica M ^a   Fuhrman, Barbara J ^a   Xu, Xia ^b   Falk, Roni T ^a   Keefer, Larry K ^a   Veenstra, Timothy D ^b   Hoover, Robert N ^a   Ziegler, Regina G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; ESTRADIOL; ESTRIOL; ESTRONE;

ADULT; ARTICLE; ASIAN AMERICAN; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN URINE LEVEL; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; POPULATION RESEARCH; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TANDEM MASS SPECTROMETRY; URINALYSIS;

ADULT; ASIAN AMERICANS; CHROMATOGRAPHY, LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; RADIOIMMUNOASSAY; TANDEM MASS SPECTROMETRY;

EID: 74549141411     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0643     Document Type: Article

References (33)

1. Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition. Endocr Relat Cancer 2005;12:1071-82.
2. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
3. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004;96:1856-65.
4. Zeleniuch-Jacquotte A, Toniolo P, Levitz M, et al. Endogenous estrogens and risk of breast cancer by estrogen receptor status: a prospective study in postmenopausal women. Cancer Epidemiol Biomarkers Prev 1995;4:857-60.
5. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-Hydroxyestrone: the 'good' estrogen. J Endocrinol 1996;150 Suppl:S259-65.
6. Kabat GC, O'Leary ES, Gammon MD, et al. Estrogen metabolism and breast cancer. Epidemiology 2006;17:80-8.
7. Sepkovic DW, Bradlow HL. Estrogen hydroxylation - the good and the bad. Ann N Y Acad Sci 2009;1155:57-67.
8. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
9. Tsutsui T, Tamura Y, Yagi E, Barrett JC. Involvement of genotoxic effects in the initiation of estrogen-induced cellular transformation: studies using Syrian hamster embryo cells treated with 17β-estradiol and eight of its metabolites. Int J Cancer 2000;86:8-14.
10. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy- and 16α-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008;17:2029-35.
11. Ho GH, Luo XW, Ji CY, Foo SC, Ng EH. Urinary 2/16α-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore 1998;27:294-9.
12. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997;6:505-9.
13. Meilahn EN, De Stavola B, Allen DS, et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998;78:1250-5.
14. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16α-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000; 11:635-40.
15. 1) in postmenopausal women with and without breast cancer. Environ Health Perspect 1997;105 Suppl 3:601-5.
16. Ursin G, London S, Stanczyk FZ, et al. Urinary 2-hydroxyestrone/ 16α-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:1067-72.
17. Ursin G, London S, Yang D, et al. Urinary 2-hydroxyestrone/16α- hydroxyestrone ratio and family history of breast cancer in premenopausal women. Breast Cancer Res Treat 2002;72:139-43.
18. Ursin G, Wilson M, Henderson BE, et al. Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and White women? Cancer Res 2001;61:3326-9.
19. Bradlow HL, Davis DL, Lin G, Sepkovic D, Tiwari R. Effects of pesticides on the ratio of 16α/2-hydroxyestrone: a biologic marker of breast cancer risk. Environ Health Perspect 1995;103 Suppl 7:147-50.
20. Falk RT, Fears TR, Xu X, et al. Urinary estrogen metabolites and their ratio among Asian American women. Cancer Epidemiol Biomarkers Prev 2005;14:221-6.
21. Lee JS, Ettinger B, Stanczyk FZ, et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab 2006;91:3791-7.
22. Santen RJ, Demers L, Ohorodnik S, et al. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 2007;72: 666-71.
23. Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev 2007;16:1713-9.
24. Xu X, Keefer LK, Ziegler RG, Veenstra TD. A liquid chromatographymass spectrometry method for the quantitative analysis of urinary endogenous estrogen metabolites. Nat Protoc 2007;2:1350-5.
25. Xu X, Roman JM, Issaq HJ, Keefer LK, Veenstra TD, Ziegler RG. Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Anal Chem 2007;79:7813-21.
26. Xu X, Veenstra TD, Fox SD, et al. Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Anal Chem 2005;77:6646-54.
27. Falk RT, Rossi SC, Fears TR, et al. A new ELISA kit for measuring urinary 2-hydroxyestrone, 16α-hydroxyestrone, and their ratio: reproducibility, validity, and assay performance after freeze-thaw cycling and preservation by boric acid. Cancer Epidemiol Biomarkers Prev 2000;9:81-7.
28. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 1993;85: 1819-27.
29. Flores OR, Sun L, Vaziri ND, Miyada DS. Colorimetric rate method for the determination of creatinine as implemented by the Beckman Creatinine Analyzer 2. Am J Med Technol 1980;46:792-8.
30. Bradlow HL, Sepkovic DW, Klug T, Osborne MP. Application of an improved ELISA assay to the analysis of urinary estrogen metabolites. Steroids 1998;63:406-13.
31. Klug TL, Bradlow HL, Sepkovic DW. Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16α-hydroxyestrone in urine. Steroids 1994;59:648-55.
32. Hsing AW, Stanczyk FZ, Belanger A, et al. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. Cancer Epidemiol Biomarkers Prev 2007;16:1004-8.
33. Ziegler RG, Rossi SC, Fears TR, et al. Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16α-hydroxyestrone in urine. Environ Health Perspect 1997;105 Suppl 3:607-14.